M&T Bank
TCRR

M&T Bank’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

M&T Bank’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,349
Closed -$156K – 1634
2021
Q3 		$156K Buy
18,349
+6,581
+56% +$93K ﹤0.01% 1461
2021
Q2 		$193K Hold
11,768
– – ﹤0.01% 1471
2021
Q1 		$260K Sell
11,768
-2,042
-15% -$55.7K ﹤0.01% 1304
2020
Q4 		$427K Hold
13,810
– – ﹤0.01% 1143
2020
Q3 		$281K Hold
13,810
– – ﹤0.01% 1270
2020
Q2 		$212K Buy
13,810
+934
+7% +$10.8K ﹤0.01% 1357
2020
Q1 		$100K Buy
12,876
+1,749
+16% +$21.4K ﹤0.01% 1422
2019
Q4 		$159K Buy
+11,127
New +$172K ﹤0.01% 1290

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

M&T Bank's TCRR Position: Q4 2021 in Review

M&T Bank sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 18,349 shares — an estimated $156K sold.

M&T Bank first reported a position in TCRR in Q4 2019 and held it in 8 quarters. The position peaked at $427K in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • M&T Bank reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • M&T Bank sold 18,349 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $156K.
  • M&T Bank first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2019 and held it in 8 quarters.
  • M&T Bank's TCR2 Therapeutics Inc. Common Stock position peaked at $427K in Q4 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on M&T Bank's 13F filing for Q4 2021, filed 7 Feb 2022.